EU's CHMP gives nod to Merck and Cardiome's Brinavess
This article was originally published in Scrip
The EU's CHMP has supported the approval of Merck & Co/Cardiome Pharma's Brinavess (vernakalant HCl) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The opinion covers its use for non-surgery patients with atrial fibrillation of seven days or less and for post-cardiac surgery patients with atrial fibrillation of three days or less duration.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.